Evolving treatments for advanced gastric cancer: appraisal of the survival trend

被引：7

作者：

Roberto, Michela ^{[1
]}

Romiti, Adriana ^{[1
]}

Onesti, Concetta Elisa ^{[1
]}

Zullo, Angelo ^{[2
]}

Falcone, Rosa ^{[1
]}

Marchetti, Paolo ^{[1
]}

机构：

[1] Sapienza Univ, St Andrea Hosp, Clin & Mol Med Dept, Via Grottarossa 1035, I-00189 Rome, Italy

[2] Nuovo Regina Margherita Hosp, Gastroenterol & Digest Endoscopy, Rome, Italy

来源：

EXPERT REVIEW OF ANTICANCER THERAPY | 2016年 / 16卷 / 07期

关键词：

Advanced gastric cancer; chemotherapy; target therapy; metronomic chemotherapy; immunotherapy; RANDOMIZED PHASE-III; ESOPHAGOGASTRIC JUNCTION ADENOCARCINOMA; CHEMOTHERAPY-NAIVE PATIENTS; PREVIOUSLY TREATED PATIENTS; IRINOTECAN PLUS CISPLATIN; LOW-DOSE CAPECITABINE; OPEN-LABEL; COMBINATION CHEMOTHERAPY; 2ND-LINE CHEMOTHERAPY; 1ST-LINE TREATMENT;

D O I：

10.1080/14737140.2016.1184979

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Introduction and areas covered: We analysed the results of the main clinical studies looking at patients with advanced gastric or esophagogastric junction cancer, in order to differentiate between what is already clinical evidence and what is a promise for the cure of such patients. Thus, achievements from key studies, which had been purposely directed at chemotherapy, molecular target therapies and immunotherapy in both first and second-line setting were analysed. Metronomic chemotherapy, which consists of the administration of continuative low-dose anticancer drugs, was considered also. Expert commentary: It was found that patients included in experimental arms of randomized trials compared with controls have often benefited from a statistically significant extension of overall survival. However, further studies are awaited to bring new drugs into clinical practice and to validate candidate biomarkers predictive of response.

引用

页码：717 / 729

页数：13

共 92 条

[1] Multicenter Phase III Comparison of Cisplatin/S-1 With Cisplatin/Infusional Fluorouracil in Advanced Gastric or Gastroesophageal Adenocarcinoma Study: The FLAGS Trial [J].

Ajani, Jaffer A. ;

Rodriguez, Wuilbert ;

Bodoky, Gyorgy ;

Moiseyenko, Vladimir ;

Lichinitser, Mikhail ;

Gorbunova, Vera ;

Vynnychenko, Ihor ;

Garin, August ;

Lang, Istvan ;

Falcon, Silvia .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (09) :1547-1553

[2] Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin:: A study of the arbeitsgemeinschaft internistische onkologie [J].

Al-Batran, Salah-Eddin ;

Hartmann, Joerg Thomas ;

Probst, Stephan ;

Schmalenberg, Harald ;

Hollerbach, Stephan ;

Hofheinz, Ralf ;

Rethwisch, Volker ;

Seipelt, Gernot ;

Homann, Nils ;

Wilhelm, Gerhard ;

Schuch, Gunter ;

Stoehlmacher, Jan ;

Derigs, Hans Guenter ;

Hegewisch-Becker, Susanna ;

Grossmann, Johannes ;

Pauligk, Claudia ;

Atmaca, Akin ;

Bokemeyer, Carsten ;

Knuth, Alexander ;

Jaeger, Elke .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (09) :1435-1442

[3] Efficacy of weekly paclitaxel in patients with advanced gastric cancer refractory to docetaxel-based chemotherapy [J].

Ando, Takayuki ;

Hosokawa, Ayumu ;

Kajiura, Shinya ;

Itaya, Yuko ;

Ueda, Akira ;

Fujinami, Haruka ;

Nishikawa, Jun ;

Kobayashi, Takashi ;

Horikawa, Naoki ;

Tsukioka, Yuji ;

Yabushita, Kazuhisa ;

Note, Masayuki ;

Ogawa, Kohei ;

Sugiyama, Toshiro .

GASTRIC CANCER, 2012, 15 (04) :427-432

[4] Metronomics: towards personalized chemotherapy? [J].

Andre, Nicolas ;

Carre, Manon ;

Pasquier, Eddy .

NATURE REVIEWS CLINICAL ONCOLOGY, 2014, 11 (07) :413-431

[5]

Bang YJ, 2010, LANCET, V376, P1302

[6] Phase II study of sunitinib as second-line treatment for advanced gastric cancer [J].

Bang, Yung-Jue ;

Kang, Yoon-Koo ;

Kang, Won K. ;

Boku, Narikazu ;

Chung, Hyun C. ;

Chen, Jen-Shi ;

Doi, Toshihiko ;

Sun, Yan ;

Shen, Lin ;

Qin, Shukui ;

Ng, Wai-Tong ;

Tursi, Jennifer M. ;

Lechuga, Maria J. ;

Lu, Dongrui Ray ;

Ruiz-Garcia, Ana ;

Sobrero, Alberto .

INVESTIGATIONAL NEW DRUGS, 2011, 29 (06) :1449-1458

[7] Comprehensive molecular characterization of gastric adenocarcinoma [J].

Bass, Adam J. ;

Thorsson, Vesteinn ;

Shmulevich, Ilya ;

Reynolds, Sheila M. ;

Miller, Michael ;

Bernard, Brady ;

Hinoue, Toshinori ;

Laird, Peter W. ;

Curtis, Christina ;

Shen, Hui ;

Weisenberger, Daniel J. ;

Schultz, Nikolaus ;

Shen, Ronglai ;

Weinhold, Nils ;

Keiser, David P. ;

Bowlby, Reanne ;

Sipahimalani, Payal ;

Cherniack, Andrew D. ;

Getz, Gad ;

Liu, Yingchun ;

Noble, Michael S. ;

Pedamallu, Chandra ;

Sougnez, Carrie ;

Taylor-Weiner, Amaro ;

Akbani, Rehan ;

Lee, Ju-Seog ;

Liu, Wenbin ;

Mills, Gordon B. ;

Yang, Da ;

Zhang, Wei ;

Pantazi, Angeliki ;

Parfenov, Michael ;

Gulley, Margaret ;

Piazuelo, M. Blanca ;

Schneider, Barbara G. ;

Kim, Jihun ;

Boussioutas, Alex ;

Sheth, Margi ;

Demchok, John A. ;

Rabkin, Charles S. ;

Willis, Joseph E. ;

Ng, Sam ;

Garman, Katherine ;

Beer, David G. ;

Pennathur, Arjun ;

Raphael, Benjamin J. ;

Wu, Hsin-Ta ;

Odze, Robert ;

Kim, Hark K. ;

Bowen, Jay .

NATURE, 2014, 513 (7517) :202-209

[8]

Browder T, 2000, CANCER RES, V60, P1878

[9] A multicenter phase II trial of single-agent cetuximab in advanced esophageal and gastric adenocarcinoma [J].

Chan, J. A. ;

Blaszkowsky, L. S. ;

Enzinger, P. C. ;

Ryan, D. P. ;

Abrams, T. A. ;

Zhu, A. X. ;

Temel, J. S. ;

Schrag, D. ;

Bhargava, P. ;

Meyerhardt, J. A. ;

Wolpin, B. M. ;

Fidias, P. ;

Zheng, H. ;

Florio, S. ;

Regan, E. ;

Fuchs, C. S. .

ANNALS OF ONCOLOGY, 2011, 22 (06) :1367-1373

[10] Salvage chemotherapy of biweekly irinotecan plus S-1 (biweekly IRIS) in previously treated patients with advanced gastric cancer [J].

Chon, Hong Jae ;

Rha, Sun Young ;

Park, Hyung Soon ;

Shin, Sang Joon ;

Kim, Hyo Song ;

Roh, Jae Kyung ;

Noh, Sung Hoon ;

Chung, Hyun Cheol ;

Jeung, Hei-Cheul .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 68 (04) :991-999

← 1 2 3 4 5 6 7 8 9 10 →